Roquefort Investments

Roquefort Therapeutics is a LSE Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company is focused on developing first in class Midkine inhibiting RNA therapeutic drugs for the treatment of cancer, chronic inflammatory, autoimmune disorder and COVID-19. Recent progress within RNA therapeutics has led to a reduction in drug development timelines and costs, increasing the chance of early value creation.

MIDKINE – A NOVEL THERAPEUTIC DISEASE TARGET

Through extensive research resulting in validation through publication in over 1,000 scientific journals, Roquefort Therapeutics has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Roquefort Therapeutics holds the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). Roquefort Therapeutics pre-clinical programme is currently underway with an initial focus on cancer treatment aiming to improve immunotherapy responses.

LATEST ANNOUNCEMENTS

Regulatory News

IF YOU HAVE ANY QUESTIONS, PLEASE GET IN TOUCH